Numerous studies have demonstrated that inflammatory markers, such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), are associated with adverse prognosis in various cancer types [4–7]. This evidence concerns the gene CRP and cancer.